-
Product Insights
Classic Solar PV Park
Classic Solar PV Park is a solar PV project located in Perlis, Malaysia. The project is owned and being developed by Classic Solar Farm Sdn Bhd. The project is at the permitting stage. Empower your strategies with our Classic Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
Yanzhou Classic Heavy Industry Jining Solar PV Plant
Yanzhou Classic Heavy Industry Jining Solar PV Plant is a solar PV project located in Shandong, China. The project is owned and developed by Zhejiang Unisun Energy Co Ltd. The project came online in 2017. Empower your strategies with our Yanzhou Classic Heavy Industry Jining Solar PV Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the...
-
Product Insights
NewLikelihood of Approval Analysis for Prurigo
Overview How likely is it that the drugs in Prurigo will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prurigo Overview Prurigo nodularis (PN) is a skin disease characterized by pruritic (itchy)...
-
Product Insights
NewLikelihood of Approval Analysis for Primary Mediastinal B-Cell Lymphoma
Overview How likely is it that the drugs in Primary Mediastinal B-Cell Lymphoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Mediastinal B-Cell Lymphoma Overview Primary Mediastinal B-Cell Lymphoma (PMBCL)...
-
Product Insights
NewLikelihood of Approval Analysis for Chronic Obstructive Pulmonary Disease (COPD)
Overview How likely is it that the drugs in Chronic Obstructive Pulmonary Disease (COPD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chronic Obstructive Pulmonary Disease (COPD) Overview Chronic obstructive pulmonary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sintilimab in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sintilimab in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sintilimab in Metastatic Melanoma Drug Details: Sintilimab (Tyvyt) is a monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sintilimab in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sintilimab in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sintilimab in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sintilimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Sintilimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANX-005 in Guillain-Barre Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANX-005 in Guillain-Barre Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANX-005 in Guillain-Barre Syndrome Drug Details: ANX-005 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TQB-2858 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-2858 in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2858 in Nasopharyngeal Cancer Drug Details: TQB-2858 is under development for the...